

1 **Antibody responses to SARS-CoV-2 train machine learning to assign likelihood of past**
2 **infection during virus emergence in Sweden**

3

4 Xaquín Castro Dopico^{1#}, Leo Hanke^{1°}, Daniel J. Sheward^{1°}, Sandra Muschiol², Soo Aleman³,
5 Murray Christian¹, Nastasiya F. Grinberg⁴, Monika Adori¹, Laura Perez Vidakovics¹, Changll
6 Kim¹, Sharesta Khoenkhoen¹, Pradeepa Pushparaj¹, Ainhua Moliner Morro¹, Marco
7 Mandolesi¹, Marcus Ahl³, Mattias Forsell⁵, Jonathan Coquet¹, Martin Corcoran¹, Joanna
8 Rorbach^{6,7}, Joakim Dillner⁸, Gordana Bogdanovic², Gerald McInerney¹, Tobias Allander^{1,2},
9 Chris Wallace^{4,9*}, Ben Murrell^{1*}, Jan Albert^{1,2*}, Gunilla B. Karlsson Hedestam^{1#}

10

11 Affiliations:

12 ¹Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm 171 77, Sweden

13 ²Department of Clinical Microbiology, Karolinska University Hospital, Stockholm 171 76, Sweden

14 ³Department of Infectious Diseases, Karolinska Universitetssjukhuset, Huddinge 141 52, Sweden

15 ⁴Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Jeffrey Cheah Biomedical Centre,
16 Cambridge Biomedical Campus, University of Cambridge, Cambridge, CB2 0AW

17 ⁵Department of Clinical Microbiology, Umeå Universitet, Umeå 901 85, Sweden

18 ⁶Department of Molecular Biochemistry & Biophysics, Karolinska Institutet, Stockholm 171 77, Sweden

19 ⁷Max Planck Institute-Biology of Ageing, Karolinska Institutet Laboratory, Stockholm 171 77, Sweden

20 ⁸Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Huddinge 141 52, Sweden

21 ⁹MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge CB2 0SR, United Kingdom

22

23 °*Equal contribution

24 #Correspondence

25

26

27

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 **Abstract**

29

30 Serology is critical for understanding pathogen-specific immune responses, but is fraught with
31 difficulty, not least because the strength of antibody (Ab) response varies greatly between
32 individuals and mild infections generally generate lower Ab titers¹⁻³. We used robust IgM, IgG
33 and IgA Ab tests to evaluate anti-SARS-CoV-2 responses in individuals PCR+ for virus RNA
34 ($n=105$) representing different categories of disease severity, including mild cases. All PCR+
35 individuals in the study became IgG-positive against pre-fusion trimers of the virus spike (S)
36 glycoprotein, but titers varied greatly. Elevated IgA, IL-6 and neutralizing responses were
37 present in intensive care patients. Additionally, blood donors and pregnant women ($n=2,900$)
38 sampled throughout the first wave of the pandemic in Stockholm, Sweden, further
39 demonstrated that anti-S IgG titers differed several orders of magnitude between individuals,
40 with an increase of low titer values present in the population at later time points^{4,5}. To
41 improve upon current methods to identify low titers and extend the utility of individual
42 measures^{6,7}, we used our PCR+ individual data to train machine learning algorithms to assign
43 likelihood of past infection. Using these tools that assigned probability to individual responses
44 against S and the receptor binding domain (RBD), we report SARS-CoV-2-specific IgG in 13.7%
45 of healthy donors five months after the peak of spring COVID-19 deaths, when mortality and
46 ICU occupancy in the country due to the virus were at low levels. These data further our
47 understanding of antibody responses to the virus and provide solutions to problems in
48 serology data analysis.

49

50 Significance statement:

51 Antibody testing provides critical clinical and epidemiological information during an emerging
52 disease pandemic. We developed robust SARS-CoV-2 IgM, IgG and IgA antibody tests and
53 profiled COVID-19 patients and exposed individuals throughout the outbreak in Stockholm,
54 Sweden, where full societal lockdown was not employed. As well as elucidating several
55 disease immunophenotypes, our data highlight the challenge of identifying low IgG titer
56 individuals, who comprise a significant proportion of the population following
57 mild/asymptomatic infection, especially as antibody titers wane following peak responses. To
58 provide a solution to this, we used SARS-CoV-2 PCR+ individual data to develop machine
59 learning approaches that assigned *likelihood of past infection* to blood donors and pregnant
60 women, improving the accuracy and utility of individual and population-level Ab measures.

61

62

63 Introduction

64 Characterization of the humoral response to nascent SARS-CoV-2 outbreaks is central to
65 optimizing approaches to the pandemic and further our understanding of human
66 immunology^{8,9}. Here, we followed the first wave of the pandemic in Stockholm, Sweden,
67 characterizing Ab responses in severely ill COVID-19 patients and exposed healthy individuals.

68

69 Despite the plethora of Ab testing and phenotyping for SARS-CoV-2¹⁰⁻¹⁷, consensus on several
70 key issues remains outstanding. For instance, the majority of data are derived from
71 commercial, mass-produced kits utilizing spike derivatives (e.g. S1 or S2 domains) or the
72 nucleocapsid to detect pathogen-specific antibodies^{10,18,19}. Many of these assays suffer from
73 epitope loss/modification²⁰, cross-reactivity^{10,21} and suboptimal sensitivity²²⁻²⁵. Here, we
74 developed highly sensitive and specific ELISA protocols based on in-house native-like pre-
75 fusion-stabilized spike (S) trimers²⁶ and the smaller ACE-2 receptor-binding domain (RBD),
76 and used them in tandem to evaluate anti-viral Ab responses. As S and the RBD are required
77 for ACE-2-mediated cell entry, we also examined virus neutralisation capacity and isotype
78 levels alongside a descriptive set of clinical features.

79

80 Aside from the target antigen, a major consideration for Ab testing concerns setting the assay
81 cut-off for positivity. Commonly, 3 or 6 standard deviations (SD) from the mean of negative
82 controls is used²⁷⁻²⁹, which is highly dependent on a representative set of negative control
83 sera - significantly affecting seroprevalence estimates and individual clinical management³⁰.
84 It is important to note that humoral responses within the population are not so much *positive*
85 or *negative*, but rather represent a wide spectrum², highlighting the need for more
86 quantitative tools to examine low titer individuals. To obtain accurate seroprevalence
87 estimates in key community groups, we strictly controlled our assay with a large number of
88 historical controls ($n=595$, repeatedly analyzed alongside test samples) and used tandem anti-
89 S and RBD responses from SARS-CoV-2 PCR+ individuals to train machine learning (ML)
90 algorithms on ELISA measurements.

91

92 Developing these approaches, that assigned likelihood of past infection to each data point
93 (values and code openly available), we sampled 100 blood donors and 100 pregnant women
94 per week throughout the outbreak in Stockholm. Both groups are a good proxy for population
95 health. Furthermore, blood donors serve as an important clinical resource (including for
96 COVID-19 plasma therapy), while pregnant women require close clinical monitoring with
97 respect to fetal-maternal health and are known to employ poorly characterized
98 immunological mechanisms impacting infectious pathology³¹⁻³³. The study was terminated
99 when new cases, mortality and ICU occupancy were at low levels. As Sweden did not impose
100 a strict lockdown in response to the pandemic, these data provide a contrast to comparable
101 settings where social lockdown was not imposed.

102

103 Results

104

105 Study samples are detailed in Table 1.

106

107 Antibody test development

108 We developed ELISA protocols to profile IgM, IgG and IgA specific for a stabilized spike (S)
109 glycoprotein trimer²⁶, the RBD, and the internal viral nucleocapsid (N). The two S antigens
110 were produced in mammalian cells (Fig. S1A) and the trimer conformation was confirmed in
111 each batch by cryo-EM³⁴. A representative subset of study samples ($n = 230$, Fig S1) was used
112 for assay development (Fig. S1B). No IgG reactivity was recorded amongst the negative
113 control samples during test development, although two individuals who were PCR-positive
114 for endemic coronavirus-positive (ECV+) displayed reproducible IgM reactivity to SARS-CoV-2
115 N and S, and two 2019 blood donors had low anti-S IgM reactivity (Fig. S1C). Thus, further
116 investigation is required to establish the contribution of cross-reactive memory and germline
117 immunoglobulin alleles to SARS-CoV-2 responses³⁵. We did not observe reproducible IgG
118 reactivity to S or RBD across all 595 historical controls in the study.

119

120 Our assay revealed a greater than 10,000-fold difference in anti-viral IgG titers between Ab-
121 positive individuals when examining serially diluted sera. In SARS-CoV-2 PCR+ individuals,
122 anti-viral IgG titers were comparable for S ($EC_{50}=3,064$; 95% CI [1,197 - 3,626]) and N
123 ($EC_{50}=2,945$; 95% CI [543 - 3,936]) and lower for RBD [$EC_{50}=1,751$; 95% CI 966 - 1,595]. A
124 subset (*ca.* 10%) of the SARS CoV-2-confirmed individuals in test development did not have
125 detectable IgG responses against N (Fig. S1D), as previously reported¹⁰. Therefore, we did not
126 explore responses to N further.

127

128 Elevated anti-viral Ab titers are associated with increased disease severity

129 We next screened all SARS-CoV-2 PCR+ individuals collected for the study ($n=105$) and
130 detected potent IgG responses against S in all participants, and against RBD in 97% of persons
131 (Fig. 1A and S2A). In healthy blood donors and pregnant women, titers varied greatly but were
132 generally lower (Fig. 1A and S2A). In PCR+ patients, IgM and IgA responses against S and RBD
133 were generally weaker and more variable between individuals than the IgG response (Fig. 1B
134 and S2B). Therefore, we sought to investigate whether isotype titers segregated with clinical
135 features.

136

137 To achieve this, SARS-CoV-2 PCR+ individuals ($n=105$) were grouped with regards to their
138 disease severity: Category 1 – *non-hospitalized (mild and asymptomatic infections)*; Category
139 2 – *hospitalized*; Category 3 – *intensive care (on mechanical ventilation)* (Table 1). In all PCR+
140 individuals, anti-S and anti-RBD responses were highly correlated (Fig. S2C) and multivariate
141 analyses revealed that increased anti-viral IgM, IgG and IgA were positively correlated with
142 disease severity (Supp. Table 1), in line with the lower titers observed in blood donors and
143 pregnant women, who did not have signs or symptoms of COVID-19 when they were sampled.

144 Severe disease was most associated with virus-specific IgA, suggestive of mucosal disease³⁶,
145 as well as elevated serum IL-6 (Fig. 1C and S2D), a cytokine that feeds Ab production³⁷⁻⁴⁰. IL-
146 6 is dysregulated in several common non-communicable diseases⁴¹⁻⁴³ and during acute
147 respiratory distress syndrome⁴⁴, risk factors for COVID-19-associated mortality^{45,46}.
148 Interestingly, we observed a lack of association between IL-6 and IgM levels, supporting that
149 levels of the cytokine and IgA mark a protracted, severe clinical course of COVID-19. IgA anti-
150 RBD responses were lower in non-hospitalized and hospitalized females as compared to
151 males, trending similarly for S (Fig. S3A) and in line with females developing less severe
152 disease⁴⁷.

153

154 In our study, PCR+ individual anti-viral IgG levels were maintained two months post-disease
155 onset/positive PCR test, while IgM and IgA decreased, in agreement with their circulating $t_{1/2}$
156 and viral clearance (Fig. S3B). In longitudinal patient samples (sequential serum sampling of
157 10 PCR+ individuals in the study) where we observed seroconversion, IgM, IgG and IgA peaked
158 with similar kinetics when all three isotypes developed, although IgA was not always
159 generated in Category 1 and 2 individuals (Fig 1D). Overall, disease severity showed the most
160 consistent relationship with any measure and was the primary predictor of Ab levels (Fig. S3C
161 and D).

162

163 We next characterized the virus neutralizing Ab response, a key parameter for understanding
164 the potential for protective humoral immune responses and the selection of plasma therapy
165 donors. Benefitting from a robust *in vitro* pseudotype virus neutralization assay⁴⁸, we
166 measured serum inhibition of viral cell entry and detected neutralizing antibodies in the
167 serum of all SARS-CoV-2 PCR+ individuals ($n=48$), and in all except two healthy Ab-positive
168 donors screened ($n=56$). Neutralizing responses were not seen in samples before
169 seroconversion (Fig. 1D) or negative controls. A large range of neutralizing ID₅₀ titers was
170 apparent, with binding and neutralizing Ab levels being highly correlated (Fig. S3D). The
171 strongest neutralizing responses were observed in samples from patients on mechanical
172 ventilation in intensive care (Category 3, g.mean ID₅₀=5,058; 95% CI [2,422 - 10,564]), in-
173 keeping with their elevated Ab response (Fig 1E). Sera from healthy blood donors and
174 pregnant women also displayed neutralizing responses, but consistent with the binding data
175 were less potent than those observed in individuals with severe disease (ID₅₀=600; 95% CI
176 [357 - 1,010] and ID₅₀=350; 95% CI [228 - 538], respectively, Fig. 1F). Across the two antigens
177 and three isotypes, anti-RBD IgG levels were most strongly correlated with neutralization.

178

179 Probabilistic seroprevalence estimates in blood donors and pregnant women

180 As Stockholm is a busy urban area and Sweden did not impose strict lockdown in response to
181 SARS-CoV-2 emergence, we sought to better understand the frequency and nature of anti-
182 viral responses in healthy blood donors and pregnant women sampled throughout the first
183 outbreak (March 30 - August 23rd 2020) (Fig. 2A). However, critical to accurate individual
184 measures and seroprevalence estimates is the decision about whether a sample is defined as

185 positive or not. For example, current clinically approved tests use a ratio between a
186 “representative” positive and negative serum calibrator to determine positivity, although we
187 show here that these are highly variable.

188
189 To improve our understanding of the assay boundary, we repeatedly analyzed a large number
190 of historical (SARS-CoV-2-negative) controls (blood donors from the spring of 2019, $n=595$)
191 alongside test samples throughout the study. We considered the spread of negative values
192 critical, since the use of a small and unrepresentative set of controls can lead to an incorrectly
193 set threshold and errors in the seroprevalence measurement. This is illustrated by the random
194 sub-sampling of non-overlapping groups of negative controls, resulting in a 40% difference in
195 the seroprevalence estimate (Fig. S4A). Seroprevalence in the healthy cohorts according to
196 conventional 3 and 6 SD cut-offs are shown in Fig. 2C.

197
198 The fact that many healthy donor test samples had optical densities between the 3 and 6 SD
199 cut-offs for both or a single antigen (Fig. 2B and C), highlights the problem of assigning case
200 to *low responder* values. Therefore, to exploit individual titers and improve our statistical
201 estimates, we used the data from PCR+ individuals (Fig. 1) and our negative controls (Fig. S4B)
202 to train machine learning (ML) algorithms to assign likelihood of past infection. A small cohort
203 of seropositive individuals among Karolinska University Hospital staff ($n=33$) provided
204 additional low titer training values four months post SARS-CoV-2+ PCR (Fig. S4C).

205
206 After comparing different methods for this purpose (Materials & Methods), we found that
207 logistic regression (LOG) achieved the highest sensitivity, while linear discriminant analysis
208 (LDA) showed the best specificity. LOG and LDA both model log odds of a sample being case
209 as a linear equation with a resulting linear decision boundary, but differ in how the
210 coefficients for the linear models are estimated from the data. When applied to the Ab
211 response data, the output of LOG and LDA is the probability of each new sample being case.
212 Therefore, we generated an equal-weighted ensemble learner (*ENS*) from the output of LOG
213 and LDA that maximized sensitivity, specificity and consistency across different cross-
214 validation strategies (Fig. 2D and S4D). While weekly rates varied (S Table 2), the *ENS* learner
215 identified 13.7% seroprevalence in healthy blood donors and pregnant women at the last
216 sampling week (Supp. Table 2). Importantly, *ENS* identified 155 (5.3%) blood donor and
217 pregnant women measures to be associated with some degree of uncertainty, encouraging
218 follow-up investigation in given cases (Fig. 2E and S4E).

219
220 Finally, to model population changes in seroprevalence over time, we developed and
221 validated a cut-off-independent Bayesian ML framework able to share information between
222 sampling weeks⁴⁹ (Fig. 2F and Materials & Methods). Using this model on the combined BD
223 and PW data, we found an almost linear increase in seroprevalence since the start of the
224 pandemic (Fig. 2E), consistent with continued virus spread in the Stockholm population during
225 the study period. The results mirrored the results obtained using *ENS*, yielding a

226 seroprevalence of 13.2% (95% Bayesian CI [10.1-16.8]) at the end of the study period (Supp.
227 Table 3). We propose that these tools and related approaches be used to facilitate future
228 antibody measures and better characterize Ab test uncertainty at individual and population
229 levels.
230

231 Discussion

232

233 Serology remains the *gold standard* for estimating previous exposure to pathogens and
234 benefits from a large historical literature. Although the concept of herd immunity is based
235 upon the study of antibodies, worryingly, there is no standardization for the many SARS-CoV-
236 2 Ab tests currently available. Globally, hospital staff and health authorities are struggling
237 with test choices, negatively impacting individual outcomes and efforts to contain the
238 pandemic.

239

240 Benefitting from a robust antibody test developed alongside a diagnostic clinical laboratory
241 responsible for monitoring sero-reactivity during the pandemic, we profiled SARS-CoV-2 Ab
242 responses in three cohorts of clinical interest. COVID-19 patients receiving intensive care
243 showed the highest anti-viral Ab titers, developing augmented serum IgA and IL-6 with
244 worsening disease. Isotype-level measures may assist COVID-19 clinical management and
245 determine, for example, whether all critically ill patients develop class-switched mucosal
246 responses to SARS-CoV-2, potentially informing lung therapeutic delivery^{50,51}. Our
247 neutralization data showed that nearly all SARS-CoV-2 PCR+ individuals and healthy donors
248 who seroconvert, develop neutralizing Ab capable of preventing S-mediated cell entry *in vitro*.

249

250 Outside of the severe disease setting, it is critical to accurately determine who and how many
251 people have seroconverted. This is complicated by low titer values, which in some cases - and
252 increasingly with time since exposure - overlap outlier values among negative control
253 samples. Test samples with true low anti-viral titers will, therefore, fall into this range of *weak*
254 *responders* as the B lymphocyte response contracts following viral clearance, highlighting the
255 need to better understand the assay boundary in multiple dimensions. As future tests begin
256 to survey individual Ab responses to a multitude of antigens in parallel, the ML approaches
257 presented here will enable the identification of disease sub-types and facilitate longitudinal
258 measures.

259

260 We applied these tools to blood donors and pregnant women, two good sentinels for
261 population health, although they are not enriched for groups with high risk for SARS-CoV-2
262 infection, such as healthcare workers and public transportation employees, where
263 seroprevalence may be higher. Blood donors are generally working age, active and mobile
264 members of society with a good understanding of health, and pregnant women in Sweden
265 will have been advised to take precautions against infectious diseases through their
266 practitioners. Interestingly, in our study, both groups showed a similar seroprevalence during
267 the time period analyzed. Tracking these cohorts over time, we modelled seroprevalence
268 changes at the population level. We found the steep climb in Ab positivity at the start of the
269 pandemic (as the virus emerged) to increase at a slower rate during subsequent weeks,
270 reaching nearly 14% by five months from the peak of spring 2020 COVID-19 deaths in the
271 country. These data indicate that serological herd immunity to the initial outbreak was not

272 achieved in these cohorts. We terminated the study in line with the decreasing caseload and
273 number of fatalities in Sweden⁵², despite on-going virus spread in the Stockholm population.

274

275 Given the uniqueness of the public health response to the pandemic in the country⁵³, these
276 data may inform the management of this and future pandemics elsewhere. Our data also
277 highlight high inter-individual variability in anti-viral Ab responses and offer solutions for how
278 to handle this at individual and population levels.

279

280 **Materials and methods**

281

282 Human samples and ethical declaration

283 Samples from PCR+ individuals and admitted COVID-19 patients ($n=105$) were collected by
284 the attending clinicians and processed through the Departments of Medicine and Clinical
285 Microbiology at the Karolinska University Hospital. Samples were used in accordance with
286 approval by the Swedish Ethical Review Authority (registration no. 2020-02811). All personal
287 identifiers were pseudo-anonymized, and all clinical feature data were blinded to the
288 researchers carrying out experiments until data generation was complete. PCR testing for
289 SARS-CoV-2 RNA was by nasopharyngeal swab or upper respiratory tract sampling at
290 Karolinska University Hospital. As viral RNA levels were determined using different qPCR
291 platforms (with the same reported sensitivity and specificity) between participants, we did
292 not analyze these alongside other features. PCR+ individuals ($n=105$) were questioned about
293 the date of symptom onset at their initial consultation and followed-up for serology during
294 their care, up to 2 months post-diagnosis. Serum from SARS-CoV-2 PCR+ individuals was
295 collected 6-61 days post-test, with the median time from symptom onset to PCR being 5 days.
296 In addition, longitudinal samples from 10 of these patients were collected to monitor
297 seroconversion and isotype persistence.

298

299 Hospital workers at Karolinska University Hospital were invited to test for the presence of
300 SARS-CoV-2 RNA in throat swabs in April 2020 and virus-specific IgG in serum in July 2020. We
301 screened 33 PCR+ individuals to provide additional training data for ML approaches. All
302 participants provided written informed consent. The study was approved by the National
303 Ethical Review Agency of Sweden (2020-01620) and the work was performed accordingly.

304

305 Anonymized samples from blood donors ($n=100$ /week) and pregnant women ($n=100$ /week)
306 were randomly selected from their respective pools by the department of Clinical
307 Microbiology, Karolinska University Hospital. No metadata, such as age or sex information
308 were available for these samples in this study. Pregnant women were sampled as part of
309 routine for infectious diseases screening during the first trimester of pregnancy. Blood donors
310 ($n=595$) collected through the same channels a year previously were randomly selected for
311 use as negative controls. Serum samples from individuals testing PCR+ for endemic
312 coronaviruses, 229E, HKU1, NL63, OC43 ($n=20$, ECV+) in the prior 2-6 months, were used as
313 additional negative controls. The use of study samples was approved by the Swedish Ethical
314 Review Authority (registration no. 2020-01807). Stockholm County death and Swedish
315 mortality data was sourced from the ECDC and the Swedish Public Health Agency,
316 respectively. Study samples are defined in Table 1.

317

318 Serum sample processing

319 Blood samples were collected by the attending clinical team and serum isolated by the
320 department of Clinical Microbiology. Samples were anonymized, barcoded and stored at -

321 20°C until use. Serum samples were not heat-inactivated for ELISA protocols but were heat-
322 inactivated at 56°C for 60 min for neutralization experiments.

323

324 SARS-CoV-2 antigen generation

325 The plasmid for expression of the SARS-CoV-2 prefusion-stabilized spike ectodomain with a
326 C-terminal T4 fibrin trimerization motif was obtained from²⁶. The plasmid was used to
327 transiently transfect FreeStyle 293F cells using FreeStyle MAX reagent (Thermo Fisher
328 Scientific). The ectodomain was purified from filtered supernatant on Streptactin XT resin (IBA
329 Lifesciences), followed by size-exclusion chromatography on a Superdex 200 in 5 mM Tris pH
330 8, 200 mM NaCl.

331

332 The RBD domain (RVQ – QFG) of SARS-CoV-2 was cloned upstream of a Sortase A recognition
333 site (LPETG) and a 6xHIS tag, and expressed in 293F cells as described above. RBD-HIS was
334 purified from filtered supernatant on His-Pur Ni-NTA resin (Thermo Fisher Scientific), followed
335 by size-exclusion chromatography on a Superdex 200. The nucleocapsid was purchased from
336 Sino Biological.

337

338 Anti-SARS-CoV-2 ELISA

339 96-well ELISA plates (Nunc MaxiSorp) were coated with SARS-CoV-2 S trimers, RBD or
340 nucleocapsid (100 µl of 1 ng/µl) in PBS overnight at 4°C. Plates were washed six times with
341 PBS-Tween-20 (0.05%) and blocked using PBS-5% no-fat milk. Human serum samples were
342 thawed at room temperature, diluted (1:100 unless otherwise indicated), and incubated in
343 blocking buffer for 1h (with vortexing) before plating. Serum samples were incubated
344 overnight at 4°C before washing, as before. Secondary HRP-conjugated anti-human
345 antibodies were diluted in blocking buffer and incubated with samples for 1 hour at room
346 temperature. Plates were washed a final time before development with TMB Stabilized
347 Chromogen (Invitrogen). The reaction was stopped using 1M sulphuric acid and optical
348 density (OD) values were measured at 450 nm using an Asys Expert 96 ELISA reader (Biochrom
349 Ltd.). Secondary antibodies (all from Southern Biotech) and dilutions used: goat anti-human
350 IgG (2014-05) at 1:10,000; goat anti-human IgM (2020-05) at 1:1000; goat anti-human IgA
351 (2050-05) at 1:6,000. All assays of the same antigen and isotype were developed for their
352 fixed time and samples were randomized and run together on the same day when comparing
353 binding between PCR+ individuals. Negative control samples were run alongside test samples
354 in all assays and raw data were log transformed for statistical analyses.

355

356 In vitro virus neutralisation assay

357 Pseudotyped viruses were generated by the co-transfection of HEK293T cells with plasmids
358 encoding the SARS-CoV-2 spike protein harboring an 18 amino acid truncation of the
359 cytoplasmic tail²⁶; a plasmid encoding firefly luciferase; a lentiviral packaging plasmid
360 (Addgene 8455) using Lipofectamine 3000 (Invitrogen). Media was changed 12-16 hours post-
361 transfection and pseudotyped viruses harvested at 48- and 72-hours, filtered through a 0.45

362 µm filter and stored at -80°C until use. Pseudotyped neutralisation assays were adapted from
363 protocols validated to characterize the neutralization of HIV, but with the use of HEK293T-
364 ACE2 cells. Briefly, pseudotyped viruses sufficient to generate ~100,000 RLUs were incubated
365 with serial dilutions of heat-inactivated serum for 60 min at 37°C. Approximately 15,000
366 HEK293T-ACE2 cells were then added to each well and the plates incubated at 37°C for 48
367 hours. Luminescence was measured using Bright-Glo (Promega) according to the
368 manufacturer's instructions on a GM-2000 luminometer (Promega) with an integration time
369 of 0.3s. The limit of detection was at a 1:45 serum dilution.

370

371 IL-6 cytometric bead array

372 Serum IL-6 levels were measured in a subset of PCR+ serum samples ($n=64$) using an enhanced
373 sensitivity cytometric bead array against human IL-6 from BD Biosciences (Cat # 561512).
374 Protocols were carried out according to the manufacturer's recommendations and data
375 acquired using a BD Celesta flow cytometer.

376

377 Statistical analysis of SARS-CoV-2 PCR+ data

378 All univariate comparisons were performed using non-parametric analyses (Kruskal-Wallis,
379 stratified Mann-Whitney, hypergeometric exact tests and Spearman rank correlation), as
380 indicated, while multivariate comparisons were performed using linear regression of log
381 transformed measures and Wald tests. For multivariate tests, all biochemical measures (IL-6,
382 PSV ID50 neut., IgG, IgA, IgM) were log transformed to improve the symmetry of the
383 distribution. As "days since first symptom" and "days since PCR+ test" are highly correlated,
384 we cannot include both in any single analysis. Instead, we show results for one, then the other
385 (Supp. Table 1).

386

387 Probabilistic seroprevalence estimations

388 Prior to analysis, each sample OD was standardized by dividing by the mean OD of "no sample
389 controls" on that plate or other plates run on the same day. This resulted in more similar
390 distributions for 2019 blood donor samples with 2020 blood donors and pregnant volunteers,
391 as well as smaller coefficients of variation amongst PCR+ COVID patients for both SPIKE and
392 RBD.

393

394 We employed two distinct probabilistic strategies for estimating seroprevalence without
395 thresholds, each developed independently. Our machine learning approach consisted of
396 evaluating different algorithms suited to ELISA data, which we compared through ten-fold
397 cross validation (CV): logistic regression (LOG), linear discriminant analysis (LDA), and support
398 vector machines (SVM) with a linear kernel. Logistic regression and linear discriminant
399 analysis both model log odds of a sample being case as a linear equation with a resulting linear
400 decision boundary. The difference between the two methods is in how the coefficients for
401 the linear models are estimated from the data. When applied to new data, the output of
402 logistic regression and LDA is the probability of each new sample being a case. Support vector

403 machines is an altogether different approach. We opted for a linear kernel, once again
404 resulting in a linear boundary. SVM constructs a boundary that maximally separates the
405 classes (i.e. the margin between the closest member of any class and the boundary is as wide
406 as possible), hence points lying far away from their respective class boundaries do not play
407 an important role in shaping it. SVM thus puts more weight on points closest to the class
408 boundary, which in our case is far from being clear. Linear SVM has one tuning parameter C ,
409 a cost, with larger values resulting in narrower margins. We tuned C on a vector of values
410 (0.001, 0.01, 0.5, 1, 2, 5, 10) via an internal 5-fold CV with 5 repeats (with the winning
411 parameter used for the final model for the main CV iteration). We also note that the natural
412 output of SVM are class labels rather than class probabilities, so the latter are obtained via
413 the method of Platt⁵⁴.

414
415 We considered three strategies for cross-validation: i) random: individuals were sampled into
416 folds at random, ii) stratified: individuals were sampled into folds at random, subject to
417 ensuring the balance of cases:controls remained fixed and iii) unbalanced: individuals were
418 sampled into folds such that each fold was deliberately skewed to under or over-represent
419 cases compared to the total sample. We sought a method that worked equally well across all
420 cross-validation schemes, as the true proportion of cases in the test data is unknown and so
421 a good method should not be overly sensitive to the proportion of cases in the training data.
422 We found most methods worked well and chose to create an ensemble (*ENS*) method
423 combining the method with the highest sensitivity (LOG) with the highest specificity (LDA),
424 defined as an unweighted average of the probabilities generated under both.

425
426 We trained the ensemble learner on all 733 training samples and predicted the probability of
427 anti-SARS-CoV-2 antibodies in blood donors and pregnant volunteers sampled in 2020. The
428 *ENS* learner had average sensitivity > 99.1% and average specificity >99.8%. We inferred the
429 proportion of the sampled population with positive antibody status each week using multiple
430 imputation. We repeatedly (1,000 times) imputed antibody status for each individual
431 randomly according to the ensemble prediction, and then analyzed each of the 1,000 datasets
432 in parallel, combining inference using Rubin's rules, derived for the Wilson binomial
433 proportion confidence interval⁵⁵.

434
435 Our Bayesian approach is explained in detail in Christian *et al*⁴⁹. Briefly, we used a logistic
436 regression over anti-RBD and -S training data to model the relationship between the ELISA
437 measurements and the probability that a sample is antibody-positive. We adjusted for the
438 training data class proportions and used these adjusted probabilities to inform the
439 seroprevalence estimates for each time point. Given that the population seroprevalence
440 cannot increase dramatically from one week to the next, we constructed a prior over
441 seroprevalence trajectories using a transformed Gaussian Process, and combined this with
442 the individual class-balance adjusted infection probabilities for each donor to infer the
443 posterior distribution over seroprevalence trajectories.

444

445 **Data and code availability statement**

446

447 Data generated as part of the study, along with custom code for statistical analyses, is openly
448 available via our GitHub repositories: [https://github.com/MurrellGroup/
449 DiscriminativeSeroprevalence/](https://github.com/MurrellGroup/DiscriminativeSeroprevalence/) and <https://github.com/chr1swallace/seroprevalence-paper>.

450

451 **Author contributions**

452

453 GKH and XCD designed the study, analyzed the results and wrote the manuscript with input
454 from co-authors. JA, TA, JD, SM, GB, MA and SA provided the study serum samples and clinical
455 information. LH, LPV, AMM, DJS, KCI, BM and GM generated SARS-CoV-2 antigens and
456 pseudotyped viruses. XCD and MF developed the ELISA protocols and XCD generated the
457 data. DJS and BM developed and performed the neutralization assay. MCh and BM developed
458 the Bayesian framework. CW and NFG assisted with patient data statistical analyses and
459 executed machine learning approaches. MA, SK, PP, MM, JC, MCo and JR carried out wet lab
460 experiments and assisted with data analysis.

461

462 **Acknowledgments**

463

464 We would like to thank the study participants and attending clinical teams. Secondly, we
465 extend our thanks to Björn Reinius, Marc Panas, Julian Stark, Remy M. Muts and Darío Solis
466 Sayago for their input and discussion. Funding for this work was provided by a Distinguished
467 Professor grant from the Swedish Research Council (agreement 2017-00968) and NIH
468 (agreement 400 SUM1A44462-02). CW and NFG are funded by the Wellcome Trust
469 (WT107881) and MRC (MC_UP_1302/5).

470

471 **Conflict of interest**

472

473 The study authors declare no competing interests related to the work.

474

475 **References**

476

- 477 1. Altman, D., Douek, D. & Boyton, R. What policy makers need to know about COVID-19
478 protective immunity. *Lancet* (2020) doi:[https://doi.org/10.1016/S0140-
479 6736\(20\)30985-5](https://doi.org/10.1016/S0140-6736(20)30985-5).
- 480 2. Jonsson, S. *et al.* Identification of sequence variants influencing immunoglobulin
481 levels. *Nat. Genet.* (2017) doi:10.1038/ng.3897.
- 482 3. Long, Q. X. *et al.* Clinical and immunological assessment of asymptomatic SARS-CoV-2
483 infections. *Nat. Med.* (2020) doi:10.1038/s41591-020-0965-6.
- 484 4. Ibarondo, F. J. *et al.* Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild
485 Covid-19. *The New England Journal of Medicine* (2020) doi:10.1056/NEJMc2025179.

- 486 5. Choe, P. *et al.* Waning antibody responses in asymptomatic and symptomatic SARS-
487 CoV-2 infection. *Emerg Infect Dis* **27**, DOI: 10.3201/eid2701.203515 (2020).
- 488 6. MacCallum, R. C., Zhang, S., Preacher, K. J. & Rucker, D. D. On the practice of
489 dichotomization of quantitative variables. *Psychol. Methods* (2002)
490 doi:10.1037//1082-989x.7.1.19.
- 491 7. Altman, D. G. & Royston, P. The cost of dichotomising continuous variables. *British*
492 *Medical Journal* (2006) doi:10.1136/bmj.332.7549.1080.
- 493 8. Davis, M. M. A Prescription for Human Immunology. *Immunity* vol. 29 835–838
494 (2008).
- 495 9. Winter, A. K. & Hegde, S. T. The important role of serology for COVID-19 control. *The*
496 *Lancet Infectious Diseases* (2020) doi:10.1016/S1473-3099(20)30322-4.
- 497 10. Long, Q. X. *et al.* Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat.*
498 *Med.* (2020) doi:10.1038/s41591-020-0897-1.
- 499 11. Zhao, J. *et al.* Antibody responses to SARS-CoV-2 in patients of novel coronavirus
500 disease 2019. *Clin. Infect. Dis.* (2020) doi:10.1093/cid/cia344.
- 501 12. Tan, W. *et al.* Viral Kinetics and Antibody Responses in Patients with COVID-19. *J Clin*
502 **doi: 10.11**, (2020).
- 503 13. Robbiani, D. F. *et al.* Convergent Antibody Responses to SARS-CoV-2 Infection in
504 Convalescent Individuals. *Nature* (2020) doi:10.1101/2020.05.13.092619.
- 505 14. Brouwer, P. J. M. *et al.* Potent neutralizing antibodies from COVID-19 patients define
506 multiple targets of vulnerability. *Science* (80-). (2020) doi:10.1126/science.abc5902.
- 507 15. Ju, B. *et al.* Human neutralizing antibodies elicited by SARS-CoV-2 infection. *Nature*
508 (2020) doi:10.1038/s41586-020-2380-z.
- 509 16. Seydoux, E. *et al.* Analysis of a SARS-CoV-2-Infected Individual Reveals Development
510 of Potent Neutralizing Antibodies with Limited Somatic Mutation. *Immunity* (2020)
511 doi:10.1016/j.immuni.2020.06.001.
- 512 17. Duan, K. *et al.* Effectiveness of convalescent plasma therapy in severe COVID-19
513 patients. *Proc. Natl. Acad. Sci. U. S. A.* (2020) doi:10.1073/pnas.2004168117.
- 514 18. Jiang, S., Hillyer, C. & Du, L. Neutralizing Antibodies against SARS-CoV-2 and Other
515 Human Coronaviruses. *Trends in Immunology* (2020) doi:10.1016/j.it.2020.03.007.
- 516 19. Van Elslande, J. *et al.* Diagnostic performance of seven rapid IgG/IgM antibody tests
517 and the Euroimmun IgA/IgG ELISA in COVID-19 patients. *Clin. Microbiol. Infect.* (2020)
518 doi:10.1016/j.cmi.2020.05.023.
- 519 20. Walls, A. C. *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
520 Glycoprotein. *Cell* (2020) doi:10.1016/j.cell.2020.02.058.
- 521 21. Cheng, M. *et al.* Cross-reactivity of antibody against SARS-coronavirus nucleocapsid
522 protein with IL-11. *Biochem. Biophys. Res. Commun.* (2005)
523 doi:10.1016/j.bbrc.2005.10.088.
- 524 22. Özçürümez, M. K. *et al.* SARS-CoV-2 antibody testing—questions to be asked. *J.*
525 *Allergy Clin. Immunol.* (2020) doi:10.1016/j.jaci.2020.05.020.
- 526 23. GeurtsvanKessel, C. H. *et al.* Towards the next phase: evaluation of serological assays
527 for diagnostics and exposure assessment. *Nat Comms* **doi: 10.10**, (2020).
- 528 24. Deeks, J. J. *et al.* Antibody tests for identification of current and past infection with
529 SARS-CoV-2. *Cochrane Database Syst. Rev.* (2020) doi:10.1002/14651858.cd013652.
- 530 25. Traugott, M. *et al.* Performance of Severe Acute Respiratory Syndrome Coronavirus 2
531 Antibody Assays in Different Stages of Infection: Comparison of Commercial Enzyme-
532 Linked Immunosorbent Assays and Rapid Tests. *J. Infect. Dis.* (2020)

- 533 doi:10.1093/infdis/jiaa305.
- 534 26. Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion
535 conformation. *Science* (80-.). (2020) doi:10.1126/science.aax0902.
- 536 27. Saraswati, K., Phanichkrivalkosil, M., Day, N. P. J. & Blacksell, S. D. The validity of
537 diagnostic cut-offs for commercial and in-house scrub typhus IgM and IgG ELISAs: A
538 review of the evidence. *PLoS Negl. Trop. Dis.* (2019)
539 doi:10.1371/journal.pntd.0007158.
- 540 28. Xu, H., Lohr, J. & Greiner, M. The selection of ELISA cut-off points for testing antibody
541 to Newcastle disease by two-graph receiver operating characteristic (TG-ROC)
542 analysis. *J. Immunol. Methods* (1997) doi:10.1016/S0022-1759(97)00128-2.
- 543 29. Greiner, M., Franke, C. R., Böhning, D. & Schlattmann, P. Construction of an intrinsic
544 cut-off value for the sero-epidemiological study of *Trypanosoma evansi* infections in a
545 canine population in Brazil: a new approach towards an unbiased estimation of
546 prevalence. *Acta Trop.* (1994) doi:10.1016/0001-706X(94)90044-2.
- 547 30. Burgess, S., Ponsford, M. J. & Gill, D. Are we underestimating seroprevalence of SARS-
548 CoV-2? *The BMJ* (2020) doi:10.1136/bmj.m3364.
- 549 31. Aghaeepour, N. *et al.* An immune clock of human pregnancy. *Sci. Immunol.* (2017)
550 doi:10.1126/sciimmunol.aan2946.
- 551 32. Mor, G. & Cardenas, I. The Immune System in Pregnancy: A Unique Complexity.
552 *American Journal of Reproductive Immunology* (2010) doi:10.1111/j.1600-
553 0897.2010.00836.x.
- 554 33. Kourtis, A. P., Read, J. S. & Jamieson, D. J. Pregnancy and infection. *New England*
555 *Journal of Medicine* (2014) doi:10.1056/NEJMra1213566.
- 556 34. Hanke, L. *et al.* An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor
557 interaction. *bioRxiv* (2020) doi:10.1101/2020.06.02.130161.
- 558 35. Herzenberg, L. A. & Herzenberg, L. A. Toward a layered immune system. *Cell* (1989)
559 doi:10.1016/0092-8674(89)90748-4.
- 560 36. Cervia, C. *et al.* Systemic and mucosal antibody secretion specific to SARS-CoV-2
561 during mild versus severe COVID-19. *bioRxiv* (2020) doi:10.1101/2020.05.21.108308.
- 562 37. Eto, D. *et al.* IL-21 and IL-6 are critical for different aspects of B cell immunity and
563 redundantly induce optimal follicular helper CD4 T cell (T_{fh}) differentiation. *PLoS One*
564 **6**, e17739 (2011).
- 565 38. Dienz, O. *et al.* The induction of antibody production by IL-6 is indirectly mediated by
566 IL-21 produced by CD4 + T cells. *J. Exp. Med.* (2009) doi:10.1084/jem.20081571.
- 567 39. Maeda, K., Mehta, H., Drevets, D. A. & Coggeshall, K. M. IL-6 increases B-cell IgG
568 production in a feed-forward proinflammatory mechanism to skew hematopoiesis
569 and elevate myeloid production. *Blood* (2010) doi:10.1182/blood-2009-07-230631.
- 570 40. Beagley, K. W. *et al.* Interleukins and IgA synthesis. Human and murine interleukin 6
571 induce high rate IgA secretion in IgA-committed B cells. *J. Exp. Med.* (1989)
572 doi:10.1084/jem.169.6.2133.
- 573 41. Mauer, J. *et al.* Signaling by IL-6 promotes alternative activation of macrophages to
574 limit endotoxemia and obesity-associated resistance to insulin. *Nat. Immunol.* (2014)
575 doi:10.1038/ni.2865.
- 576 42. Kristiansen, O. P. & Mandrup-Poulsen, T. Interleukin-6 and diabetes: The good, the
577 bad, or the indifferent? *Diabetes* (2005) doi:10.2337/diabetes.54.suppl_2.S114.
- 578 43. Ferreira, R. C. *et al.* Functional IL6R 358Ala Allele Impairs Classical IL-6 Receptor
579 Signaling and Influences Risk of Diverse Inflammatory Diseases. *PLoS Genet.* **9**, (2013).

- 580 44. Park, W. Y. *et al.* Cytokine balance in the lungs of patients with acute respiratory
581 distress syndrome. *Am. J. Respir. Crit. Care Med.* (2001)
582 doi:10.1164/ajrccm.164.10.2104013.
- 583 45. Magro, G. SARS-CoV-2 and COVID-19: Is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS
584 onset? What is there besides Tocilizumab? SGP130Fc. *Cytokine: X* (2020)
585 doi:10.1016/j.cytex.2020.100029.
- 586 46. Chua, R. L. *et al.* COVID-19 severity correlates with airway epithelium–immune cell
587 interactions identified by single-cell analysis. *Nat. Biotechnol.* (2020)
588 doi:10.1038/s41587-020-0602-4.
- 589 47. *et al.* Viral epitope profiling of COVID-19 patients reveals cross-reactivity and
590 correlates of severity. *Science (80-.)*. (2020) doi:10.1126/science.abd4250.
- 591 48. Bartosch, B. *et al.* In vitro assay for neutralizing antibody to hepatitis C virus: Evidence
592 for broadly conserved neutralization epitopes. *Proc. Natl. Acad. Sci. U. S. A.* (2003)
593 doi:10.1073/pnas.2335981100.
- 594 49. Christian, M. & Murrell, B. Discriminative Bayesian Serology: Counting Without
595 Cutoffs. *BioRxiv* (2020).
- 596 50. Larios Mora, A. *et al.* Delivery of ALX-0171 by inhalation greatly reduces respiratory
597 syncytial virus disease in newborn lambs. *MAbs* (2018)
598 doi:10.1080/19420862.2018.1470727.
- 599 51. Sheridan, C. Ablynx’s nanobody fragments go places antibodies cannot. *Nat.*
600 *Biotechnol.* (2017) doi:10.1038/nbt1217-1115.
- 601 52. Intensivvårdsregistret, S. Antal som intensivvårdas med Covid-19 per dag. *Svenska*
602 *Intensivvårdsregistrets utdataportal*
603 <https://portal.icuregsw.se/siri/report/corona.co> (2020).
- 604 53. Paterlini, M. ‘Closing borders is ridiculous’: the epidemiologist behind Sweden’s
605 controversial coronavirus strategy. *Nature* (2020) doi:10.1038/d41586-020-01098-x.
- 606 54. Platt, J. & others. Probabilistic outputs for support vector machines and comparisons
607 to regularized likelihood methods. *Adv. large margin Classif.* (1999).
- 608 55. Lott, A. & Reiter, J. P. Wilson Confidence Intervals for Binomial Proportions With
609 Multiple Imputation for Missing Data. *Am. Stat.* (2020)
610 doi:10.1080/00031305.2018.1473796.

611
612






Figure 1: Anti-SARS-CoV-2 Ab phenotypes in COVID-19 patients, PCR+ individuals, blood donors and pregnant women (A) Raw optical density (OD) anti-S and -RBD IgG responses are shown in SARS-CoV-2 PCR+ individuals ($n=105$), blood donors (BD, $n=1,500$) and pregnant women (PW, $n=1,400$). Controls, C, represent $n=595$ blood donors from spring 2019. Conventional 6 SD cut-offs shown by dotted lines. **(B)** IgM, IgG and IgA responses against S and RBD in PCR+ individuals ($n=105$), with a limited number of controls for each assay represented by open circles. **(C)** Anti-viral Ab levels are associated with disease severity, most pronounced for IgA. COVID-19 patients in the ICU category were mechanically ventilated. Anti-S and RBD responses are graphed together. **(D)** Two discordant longitudinal profiles of seroconversion and neutralisation capacity are shown. **(E)** *In vitro* pseudotyped virus neutralization ID₅₀ titers are associated with disease severity, with the highest titers observed in Cat 3 (ICU) patients. Forty-eight SARS-CoV-2 PCR+ individuals analyzed in duplicate. **(F)** Comparison of neutralization ID₅₀ titers between PCR+ individuals ($n=48$), BD ($n=28$) and PW ($n=28$), all analyzed in duplicate. Bars represent the geometric mean and P values are from a two-tailed Mann-Whitney test.


A




B




C



D



E



F




Figure 2: Probability-based seroprevalence estimates in Stockholm during the initial outbreak


(A) Study sample collection intervals are shown alongside the 14-day COVID-19 death rate per million inhabitants in Sweden and relevant countries for comparison. (B) Log-transformed un-normalized OD measurements from all BD and PW in the study. Conventional 3 (dotted red line) and 6 SD (solid red line) cut-offs are shown; calculated from $n=595$ historical controls; 100 random negative controls (C, with 95% CI of the median) are shown for each assay. (C) The percentage anti-S and -RBD IgG positive per sampling week in BD and PW show according to 3 or 6 SD cut-offs. (D) S and RBD responses from PCR+ individuals were used to train different machine learning algorithms to assign likelihood of past infection. We created an ensemble learner (ENS) from the output of logistic regression and linear discriminant analysis, providing a highly sensitive, specific and consistent multi-dimensional solution to the problem of weak reactors, and assigning each data point a probability of being positive. Conventional 3 and 6 SD cut-offs are shown for each antigen, with probabilities assigned to selected points. (E) Heatmap of assigned ENS probabilities for the top 35 BD and PW values per week, with each square representing an individual. (F) Seroprevalence (SP) estimates in Stockholm modelled over time in BD and PW using a cut-off-independent Bayesian framework.

Table 1 – Study samples


| | |
|--------------------------------------------------------|---------------------------------|
| <u>SARS-CoV-2 PCR+ individuals</u> [§] | <i>n</i> =105 |
| Females | <i>n</i> =44 (41.9%) |
| Males | <i>n</i> =61 (58.1%) |
| Median age (years) | 53.0 (49-61) |
| Females | 51.5 (48-56.2) |
| Males | 55.0 (49-63) |
| Non-hospitalized | <i>n</i> =53 |
| Females, males | 28, 25 |
| Hospitalized patients | <i>n</i> =31 |
| Females, males | 12, 17 |
| Intensive care (ICU) patients | <i>n</i> =21 |
| Females, males | 3, 17 |
| SARS-CoV2+ PCR | <i>n</i> =105 |
| Sample collection dates | March-August 2020 |
| <u>SARS-CoV-2 PCR+ KI hospital staff</u> | <i>n</i> =33 |
| Sample collection dates | July 2020 |
| <u>Blood donors</u> | <i>n</i> =1,500 |
| Sample collection dates | Weeks 14-34 (March-August) 2020 |
| <u>Pregnant women</u> | <i>n</i> =1,400 |
| Sample collection dates | Weeks 17-34 (April-August) 2020 |
| <u>Historical blood donors</u> | <i>n</i> =595 |
| Sample collection dates | April-June 2019 |
| <u>ECV+ donors</u> | <i>n</i> =20 |
| Sample collection dates | July-December 2019 |

[§]Under the care of Karolinska University Hospital
No additional metadata available for any samples


A



medRxiv preprint doi: <https://doi.org/10.1101/2020.07.17.20155937>; this version posted October 19, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



C



D





Figure S1: Anti-SARS-CoV-2 ELISA protocol development


(A) Trimeric S and RBD were expressed in 293F cells and purified as described. (B) A random subset of PCR+ individuals, negative controls and BD were used to validate the assays for the three isotypes, these were individuals with confirmed SARS CoV-2 infection ($n=36$, from a range of disease severity categories); blood donors from the spring of 2020 ($n=100$); two sets of negative controls, blood donors from the spring of 2019 ($n=75$) and individuals PCR+ for endemic coronaviruses (ECV+) ($n=20$). (C) Two ECV+ donors, K2 and K4, showed reproducible IgM binding to S. Testing of another subset of historical controls ($n=75$) for a similar observation, two additional individuals were found to show IgM binding to S. (D) Serial dilutions of PCR+ participant serum are shown (in a representative sample, $n=40$) of titrated individuals for anti-S and anti-RBD IgG.

A


It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



B



C



D




Figure S2: Antibody phenotypes in PCR+ individuals and healthy participants

(A) Log₁₀ OD₄₅₀ anti-S and -RBD IgG responses in SARS-CoV-2 PCR+ individuals and healthy donors, with a 6 SD cut-off shown calculated from all 595 negative control values. (B) Raw OD₄₅₀ isotypic responses in PCR+ individuals. A limited number of negative controls are depicted by clear circles. (C) Anti-S vs -RBD responses in PCR+ individuals are highly correlated. (D) Elevated anti-viral Ab and serum IL-6 are associated with disease severity in PCR+ individuals, IgM and IgG.






Figure S3: Antibody phenotypes in PCR+ individuals

(A) Antibody responses according to sex for anti-S and –RBD IgA. (B) IgM and IgA titers declined with time from first symptom/SARS-CoV-2+ PCR. IgG levels were maintained during this time. *P* values from a Spearman rank correlation test. (C) Spearman's rank correlation of PCR+ dataset features and antibody levels. DOB - date of birth; d-p SymO - days post-symptom onset; d-p PCR – days post SARS-CoV-2+ PCR; PSV ID50 – neutralizing titer (D) Adjusted fold-change for dataset features in PCR+ individuals compared to category 1. The effects of age (DOB), sex, days from PCR test were considered.


A




B



C



D



E




Figure S4: Considerations and methods for SP estimates in BD and PW

(A) Random sub-sampling of non-overlapping negative controls illustrates how the range of negative control values can influence the conventional test cut-off. Depending on the control values used to set the test threshold for positivity, seroprevalence (SP) estimates vary by 40%. 600 BD and PW values are used as an example. Anti-S IgG values are shown. (B) The distribution of negative control serum values for anti-S and -RBD IgG. (C) As ML methods improve with additional data, we analyzed a small cohort ($n=33$) of PCR+ Karolinska University hospital staff (HS) for S and RBD IgG responses. $n=32$ historical controls, C, were analyzed alongside. (D) Comparison of logistic regression, linear discriminant analysis and the *ENS* learner, showing the training data set and BD and PW test samples. *ENS* was trained using 595 negative control values and 138 PCR+ individuals. (E) *ENS* identified several study BD and PW to have uncertain measurements when S and RBD responses were considered, facilitating individual re-testing.

Supplementary Table 1

COVID-19 patient multivariate analysis

Days from first symptom

Days from SARS-CoV-2+ PCR test

| IL.6 | | | | | IL.6 | | | | |
|-------------------------------------|------------|------------|------------|-----------|----------------------------------------------------|------------|------------|------------|-----------|
| | Estimate | Std. Error | t value | Pr(> t) | | Estimate | Std. Error | t value | Pr(> t) |
| (Intercept) | 1.0808524 | 0.7558497 | 1.4299833 | 0.1589412 | (Intercept) | 1.3337536 | 0.7900611 | 1.6881651 | 0.0972562 |
| Days.FFS | -0.0138028 | 0.0092132 | -1.4981536 | 0.1403806 | Days.PCR | -0.0179820 | 0.0091674 | -1.9615105 | 0.0550817 |
| Severity2 | 0.6751029 | 0.2725780 | 2.4767330 | 0.0166860 | Severity2 | 0.5419503 | 0.2784989 | 1.9459695 | 0.0569693 |
| Severity3 | 2.0818073 | 0.3139723 | 6.6305441 | 0.0000000 | Severity3 | 1.7879936 | 0.3174311 | 5.6326988 | 0.0000007 |
| SexF | -0.0048214 | 0.2490798 | -0.0193569 | 0.9846335 | SexF | -0.0418102 | 0.2496296 | -0.1674892 | 0.8676226 |
| Years | 0.0006194 | 0.0120141 | 0.0515519 | 0.9590912 | Years | -0.0002995 | 0.0127464 | -0.0234942 | 0.9813443 |
| <i>ness with 2 outliers removed</i> | | | | | <i>checking robustness with 2 outliers removed</i> | | | | |
| | Estimate | Std. Error | t value | Pr(> t) | | Estimate | Std. Error | t value | Pr(> t) |
| (Intercept) | 0.5938320 | 0.6085196 | 0.9758633 | 0.3340249 | (Intercept) | 0.7050756 | 0.6754753 | 1.0438215 | 0.3014906 |
| Days.FFS | -0.0048689 | 0.0073761 | -0.6600921 | 0.5123499 | Days.PCR | -0.0046541 | 0.0079825 | -0.5830368 | 0.5624379 |
| Severity2 | 0.6314650 | 0.2134847 | 2.9578929 | 0.0047955 | Severity2 | 0.5212971 | 0.2297047 | 2.2694227 | 0.0275018 |
| Severity3 | 1.5427576 | 0.2627737 | 5.8710497 | 0.0000004 | Severity3 | 1.3678120 | 0.2739547 | 4.9928394 | 0.0000073 |
| SexF | -0.1881632 | 0.2020666 | -0.9311939 | 0.3564134 | SexF | -0.1798193 | 0.2123891 | -0.8466500 | 0.4011457 |
| Years | 0.0047880 | 0.0095726 | 0.5001784 | 0.6192350 | Years | 0.0039051 | 0.0107259 | 0.3640784 | 0.7173046 |
| PSV.ID50 | | | | | PSV.ID50 | | | | |
| | Estimate | Std. Error | t value | Pr(> t) | | Estimate | Std. Error | t value | Pr(> t) |
| (Intercept) | 4.5012562 | 1.8338893 | 2.4544864 | 0.0193831 | (Intercept) | 5.2752610 | 1.6958032 | 3.1107742 | 0.0035845 |
| Days.FFS | -0.0150209 | 0.0222419 | -0.6753408 | 0.5040267 | Days.PCR | -0.0282459 | 0.0190912 | -1.4795302 | 0.1474633 |
| Severity2 | 1.4888195 | 0.5062151 | 2.9410804 | 0.0058489 | Severity2 | 1.4647193 | 0.4544978 | 3.2227205 | 0.0026504 |
| Severity3 | 1.4175205 | 1.0591033 | 1.3384157 | 0.1896430 | Severity3 | 1.9419796 | 0.7912711 | 2.4542533 | 0.0189450 |
| SexF | -0.1325308 | 0.4944022 | -0.2680627 | 0.7902707 | SexF | 0.1871493 | 0.4244939 | 0.4408763 | 0.6618680 |
| Years | 0.0484696 | 0.0266019 | 1.8220360 | 0.0772562 | Years | 0.0378735 | 0.0253337 | 1.4949856 | 0.1433991 |
| <i>tness with 1 outlier removed</i> | | | | | <i>checking robustness with 1 outlier removed</i> | | | | |
| | Estimate | Std. Error | t value | Pr(> t) | | Estimate | Std. Error | t value | Pr(> t) |
| (Intercept) | 4.5186312 | 1.7467553 | 2.5868713 | 0.0142822 | (Intercept) | 5.3454881 | 1.5958448 | 3.3496292 | 0.0019089 |

| | | | | |
|-----------|------------|-----------|------------|-----------|
| Days.FFS | -0.0063506 | 0.0215775 | -0.2943131 | 0.7703621 |
| Severity2 | 1.2195131 | 0.4986724 | 2.4455196 | 0.0199661 |
| Severity3 | 1.4434429 | 1.0088452 | 1.4307873 | 0.1618932 |
| SexF | -0.0004480 | 0.4750254 | -0.0009431 | 0.9992532 |
| Years | 0.0403811 | 0.0256244 | 1.5758858 | 0.1245916 |

| | | | | |
|-----------|------------|-----------|------------|-----------|
| Days.PCR | -0.0197376 | 0.0183073 | -1.0781255 | 0.2881490 |
| Severity2 | 1.2106216 | 0.4404721 | 2.7484639 | 0.0092996 |
| Severity3 | 1.9906995 | 0.7447805 | 2.6728673 | 0.0112300 |
| SexF | 0.3062324 | 0.4024577 | 0.7609059 | 0.4516688 |
| Years | 0.0297967 | 0.0240715 | 1.2378418 | 0.2237872 |

S.IgG

| | Estimate | Std. Error | t value | Pr(> t) |
|-------------|------------|------------|------------|-----------|
| (Intercept) | -0.4338183 | 0.1572226 | -2.7592622 | 0.0070039 |
| Days.FFS | 0.0056162 | 0.0018643 | 3.0124437 | 0.0033555 |
| Severity2 | 0.2636915 | 0.0582979 | 4.5231746 | 0.0000183 |
| Severity3 | 0.1553421 | 0.0760363 | 2.0429981 | 0.0439450 |
| SexF | -0.1061612 | 0.0537241 | -1.9760431 | 0.0511786 |
| Years | 0.0025710 | 0.0026281 | 0.9782727 | 0.3305330 |

S.IgG

| | Estimate | Std. Error | t value | Pr(> t) |
|-------------|------------|------------|------------|-----------|
| (Intercept) | -0.3943762 | 0.1612688 | -2.4454589 | 0.0163490 |
| Days.PCR | 0.0055996 | 0.0019357 | 2.8928024 | 0.0047551 |
| Severity2 | 0.2736918 | 0.0600135 | 4.5605006 | 0.0000155 |
| Severity3 | 0.1924181 | 0.0764924 | 2.5155192 | 0.0136010 |
| SexF | -0.0761660 | 0.0536223 | -1.4204181 | 0.1588299 |
| Years | 0.0021211 | 0.0027262 | 0.7780124 | 0.4385365 |

RBD.IgG

| | Estimate | Std. Error | t value | Pr(> t) |
|-------------|------------|------------|------------|-----------|
| (Intercept) | -0.5916830 | 0.2306770 | -2.5649851 | 0.0119546 |
| Days.FFS | 0.0034375 | 0.0027353 | 1.2566928 | 0.2120811 |
| Severity2 | 0.3166891 | 0.0855347 | 3.7024646 | 0.0003657 |
| Severity3 | 0.3183027 | 0.1115605 | 2.8531842 | 0.0053580 |
| SexF | -0.1630434 | 0.0788241 | -2.0684471 | 0.0414354 |
| Years | 0.0021569 | 0.0038560 | 0.5593721 | 0.5772819 |

RBD.IgG

| | Estimate | Std. Error | t value | Pr(> t) |
|-------------|------------|------------|------------|-----------|
| (Intercept) | -0.4864143 | 0.2323367 | -2.0935746 | 0.0390193 |
| Days.PCR | 0.0026259 | 0.0027887 | 0.9416332 | 0.3488201 |
| Severity2 | 0.3090881 | 0.0864603 | 3.5749131 | 0.0005579 |
| Severity3 | 0.3412088 | 0.1102011 | 3.0962391 | 0.0025904 |
| SexF | -0.1373444 | 0.0772525 | -1.7778632 | 0.0786949 |
| Years | 0.0009867 | 0.0039277 | 0.2512189 | 0.8021991 |

S.IgM

| | Estimate | Std. Error | t value | Pr(> t) |
|-------------|------------|------------|------------|-----------|
| (Intercept) | -0.8300628 | 0.3562796 | -2.3298074 | 0.0220285 |
| Days.FFS | -0.0117670 | 0.0042247 | -2.7852943 | 0.0065067 |
| Severity2 | 0.4216830 | 0.1321079 | 3.1919588 | 0.0019404 |
| Severity3 | 0.1256475 | 0.1723047 | 0.7292168 | 0.4677418 |
| SexF | -0.1603918 | 0.1217434 | -1.3174576 | 0.1909928 |
| Years | 0.0144308 | 0.0059556 | 2.4230696 | 0.0173698 |

S.IgM

| | Estimate | Std. Error | t value | Pr(> t) |
|-------------|------------|------------|------------|-----------|
| (Intercept) | -0.7023442 | 0.3495024 | -2.0095550 | 0.0473764 |
| Days.PCR | -0.0140527 | 0.0041950 | -3.3498589 | 0.0011693 |
| Severity2 | 0.3945068 | 0.1300616 | 3.0332313 | 0.0031359 |
| Severity3 | 0.1480218 | 0.1657746 | 0.8929099 | 0.3742101 |
| SexF | -0.0547174 | 0.1162104 | -0.4708481 | 0.6388518 |
| Years | 0.0113959 | 0.0059083 | 1.9287769 | 0.0568080 |

RBD.IgM

| | Estimate | Std. Error | t value | Pr(> t) |
|-------------|-----------------|-------------------|----------------|--------------------|
| (Intercept) | -1.0387929 | 0.4130592 | -2.5148767 | 0.0136629 |
| Days.FFS | -0.0138623 | 0.0048980 | -2.8302083 | 0.0057240 |
| Severity2 | 0.5057259 | 0.1531617 | 3.3019087 | 0.0013732 |
| Severity3 | 0.1944795 | 0.1997646 | 0.9735434 | 0.3328641 |
| SexF | -0.2399048 | 0.1411454 | -1.6996999 | 0.0926033 |
| Years | 0.0171226 | 0.0069047 | 2.4798392 | 0.0149844 |

RBD.IgM

| | Estimate | Std. Error | t value | Pr(> t) |
|-------------|-----------------|-------------------|----------------|--------------------|
| (Intercept) | -0.8655000 | 0.3973594 | -2.178129 | 0.0319255 |
| Days.PCR | -0.0172033 | 0.0047694 | -3.606981 | 0.0005008 |
| Severity2 | 0.4913299 | 0.1478708 | 3.322698 | 0.0012758 |
| Severity3 | 0.2406897 | 0.1884739 | 1.277045 | 0.2047656 |
| SexF | -0.1394645 | 0.1321230 | -1.055566 | 0.2939009 |
| Years | 0.0133309 | 0.0067174 | 1.984546 | 0.0501421 |

S.IgA

| | Estimate | Std. Error | t value | Pr(> t) |
|-------------|-----------------|-------------------|----------------|--------------------|
| (Intercept) | -0.2343625 | 0.3626807 | -0.6461952 | 0.5197793 |
| Days.FFS | -0.0097902 | 0.0043006 | -2.2764744 | 0.0251627 |
| Severity2 | 0.7529383 | 0.1344814 | 5.5988283 | 0.0000002 |
| Severity3 | 1.0042292 | 0.1754004 | 5.7253524 | 0.0000001 |
| SexF | -0.2661040 | 0.1239307 | -2.1472001 | 0.0344358 |
| Years | -0.0057710 | 0.0060626 | -0.9519015 | 0.3436685 |

S.IgA

| | Estimate | Std. Error | t value | Pr(> t) |
|-------------|-----------------|-------------------|----------------|--------------------|
| (Intercept) | -0.3012762 | 0.3728826 | -0.8079654 | 0.4211724 |
| Days.PCR | -0.0098957 | 0.0044757 | -2.2110117 | 0.0294865 |
| Severity2 | 0.6714710 | 0.1387621 | 4.8390072 | 0.0000052 |
| Severity3 | 0.9000684 | 0.1768642 | 5.0890358 | 0.0000019 |
| SexF | -0.2758111 | 0.1239844 | -2.2245634 | 0.0285297 |
| Years | -0.0041292 | 0.0063036 | -0.6550579 | 0.5140475 |

RBD.IgA

| | Estimate | Std. Error | t value | Pr(> t) |
|-------------|-----------------|-------------------|----------------|--------------------|
| (Intercept) | -0.2710503 | 0.4094717 | -0.6619513 | 0.5096753 |
| Days.FFS | -0.0180531 | 0.0048554 | -3.7181129 | 0.0003466 |
| Severity2 | 0.5614106 | 0.1518315 | 3.6975911 | 0.0003718 |
| Severity3 | 0.9648132 | 0.1980296 | 4.8720661 | 0.0000046 |
| SexF | -0.4683261 | 0.1399195 | -3.3471098 | 0.0011886 |
| Years | -0.0023814 | 0.0068447 | -0.3479188 | 0.7287046 |

RBD.IgA

| | Estimate | Std. Error | t value | Pr(> t) |
|-------------|-----------------|-------------------|----------------|--------------------|
| (Intercept) | -0.2267285 | 0.4122576 | -0.5499679 | 0.5836598 |
| Days.PCR | -0.0196414 | 0.0049483 | -3.9693438 | 0.0001418 |
| Severity2 | 0.4589973 | 0.1534149 | 2.9918687 | 0.0035499 |
| Severity3 | 0.8788819 | 0.1955404 | 4.4946297 | 0.0000200 |
| SexF | -0.4433399 | 0.1370767 | -3.2342474 | 0.0016890 |
| Years | -0.0029664 | 0.0069692 | -0.4256455 | 0.6713496 |

Supplementary Table 2

ENS learner estimates

| Type | Week | N | Estimate | lower.ci | upper.ci |
|---------------------|------|-----|---------------------|---------------------|--------------------|
| Blood donors | Wk14 | 100 | 0.0105199999999998 | 0.00186267413688987 | 0.0571124452130694 |
| Blood donors | Wk17 | 100 | 0.0599300000000007 | 0.0277067084436435 | 0.124818422697639 |
| Blood donors | Wk18 | 100 | 0.0302500000000004 | 0.0103369986968445 | 0.0852198537817097 |
| Blood donors | Wk19 | 100 | 0.0819899999999993 | 0.0420758061055538 | 0.153692847546347 |
| Blood donors | Wk20 | 100 | 0.0888300000000009 | 0.046518592804669 | 0.163045245940735 |
| Blood donors | Wk21 | 100 | 0.0606200000000007 | 0.0279295559709151 | 0.126590435953148 |
| Blood donors | Wk22 | 100 | 0.0518599999999995 | 0.0223967600811795 | 0.115503146139443 |
| Blood donors | Wk23 | 100 | 0.103139999999999 | 0.0568755500979782 | 0.179860591957947 |
| Blood donors | Wk24 | 100 | 0.0491799999999993 | 0.0208070659558649 | 0.111824427597925 |
| Blood donors | Wk25 | 100 | 0.0645900000000004 | 0.0299472449446712 | 0.133780545972474 |
| Blood donors | Wk30 | 100 | 0.14169 | 0.0843021051364242 | 0.22839998832092 |
| Blood donors | Wk31 | 100 | 0.0880700000000001 | 0.0460906749148218 | 0.161798798516266 |
| Blood donors | Wk32 | 100 | 0.13474 | 0.07991254449231 | 0.218260850763384 |
| Blood donors | Wk33 | 100 | 0.1220900000000001 | 0.0711556354845674 | 0.201571777003771 |
| Blood donors | Wk34 | 100 | 0.1813100000000001 | 0.116915378458736 | 0.270315226797433 |
| Pregnant volunteers | Wk17 | 100 | 0.02785 | 0.00854309329510716 | 0.0869623409679927 |
| Pregnant volunteers | Wk18 | 100 | 0.0593100000000001 | 0.0263543448650153 | 0.128056041293278 |
| Pregnant volunteers | Wk19 | 100 | 0.0779199999999998 | 0.0392832595316614 | 0.148676738526427 |
| Pregnant volunteers | Wk20 | 100 | 0.0613500000000007 | 0.028401055595685 | 0.12750757406586 |
| Pregnant volunteers | Wk21 | 100 | 0.0904400000000002 | 0.0482644667169825 | 0.163152425697498 |
| Pregnant volunteers | Wk22 | 100 | 0.0205599999999997 | 0.00565556676979313 | 0.0719026340509295 |
| Pregnant volunteers | Wk23 | 100 | 0.0725799999999993 | 0.0355650368403294 | 0.142429663079253 |
| Pregnant volunteers | Wk24 | 100 | 0.09021000000000021 | 0.0481585199364663 | 0.162703789795822 |
| Pregnant volunteers | Wk25 | 100 | 0.0705999999999996 | 0.0338472442954616 | 0.141419016311214 |
| Pregnant volunteers | Wk30 | 100 | 0.13676 | 0.0802505417653763 | 0.22339634766703 |
| Pregnant volunteers | Wk31 | 100 | 0.10084 | 0.0549469530519067 | 0.17785049838699 |
| Pregnant volunteers | Wk32 | 100 | 0.1025 | 0.055496584850798 | 0.181656768852696 |
| Pregnant volunteers | Wk33 | 100 | 0.0988799999999996 | 0.0537530085744113 | 0.174890088243812 |
| Pregnant volunteers | Wk34 | 100 | 0.0921200000000004 | 0.0482559484435156 | 0.168784935290148 |

| | | | | | |
|----------|------|-----|--------------------|---------------------|--------------------|
| Combined | Wk14 | 100 | 0.0105199999999998 | 0.00186267413688987 | 0.0571124452130694 |
| Combined | Wk17 | 200 | 0.0438900000000003 | 0.0227358905689 | 0.0830537591523687 |
| Combined | Wk18 | 200 | 0.0447800000000002 | 0.0231970950185039 | 0.084702634433189 |
| Combined | Wk19 | 200 | 0.0799549999999993 | 0.0494561100547252 | 0.126754068380355 |
| Combined | Wk20 | 200 | 0.0750900000000004 | 0.0456186256545027 | 0.121183433120669 |
| Combined | Wk21 | 200 | 0.0755300000000001 | 0.0462139889421297 | 0.121081899484158 |
| Combined | Wk22 | 200 | 0.0362099999999997 | 0.01767721923418 | 0.0727338989258544 |
| Combined | Wk23 | 200 | 0.0878600000000001 | 0.0555074115333125 | 0.136347182613079 |
| Combined | Wk24 | 200 | 0.0696949999999998 | 0.0417896481831635 | 0.11401710633583 |
| Combined | Wk25 | 200 | 0.067595 | 0.0396097669899812 | 0.113025523482377 |
| Combined | Wk30 | 200 | 0.139225 | 0.0959384551539447 | 0.197769606826778 |
| Combined | Wk31 | 200 | 0.0944549999999999 | 0.0605819855281929 | 0.144356990235433 |
| Combined | Wk32 | 200 | 0.11862 | 0.07965512726089 | 0.173061192324389 |
| Combined | Wk33 | 200 | 0.1104849999999999 | 0.0737258058315149 | 0.162359527188935 |
| Combined | Wk34 | 200 | 0.136715 | 0.0949178112379659 | 0.192992997104021 |

Supplementary Table 3

Bayesian framework estimates

| Weeks | low_95 CI | low_70 CI | median | high_70 CI | high_95 CI |
|-------|----------------------|----------------------|----------------------|----------------------|----------------------|
| 14 | 0.003601532073810209 | 0.010015687500615324 | 0.02436939594002145 | 0.043456945152414495 | 0.05616568875771716 |
| 15 | 0.013309857927117485 | 0.020660967591371423 | 0.032365176467805026 | 0.04686039254667125 | 0.057377820643647284 |
| 16 | 0.02043808572781734 | 0.029802245381973035 | 0.040635466265145775 | 0.05175183854151783 | 0.060108358798232966 |
| 17 | 0.028769918494488296 | 0.03854036071416008 | 0.0474550179123166 | 0.056517830868095725 | 0.06401279669503077 |
| 18 | 0.037835374202155374 | 0.04509305165735621 | 0.052891120720793466 | 0.061614679337302775 | 0.06926247627139652 |
| 19 | 0.045462175043307455 | 0.050609840723507125 | 0.05808259302264415 | 0.0667054486902604 | 0.07438983764874765 |
| 20 | 0.04989302616185007 | 0.054706576021972896 | 0.06245970619115278 | 0.07129624957262747 | 0.07830821520536643 |
| 21 | 0.0521467423382186 | 0.05791442812480507 | 0.06609758175045291 | 0.07540895724676397 | 0.08350881740670542 |
| 22 | 0.055047827319195435 | 0.06082934394956948 | 0.06969771188215743 | 0.07893154646022037 | 0.08722346458242437 |
| 23 | 0.05711768032568647 | 0.0637732596810297 | 0.07335796512117096 | 0.08312494379587673 | 0.09144734645121028 |
| 24 | 0.06014606597769269 | 0.06715508580434398 | 0.07787976883612677 | 0.08778705973980627 | 0.09682553258559098 |
| 25 | 0.06299793120194423 | 0.07069250124677944 | 0.0826946388601972 | 0.09317717560756934 | 0.10369128433164672 |
| 26 | 0.06602989547112409 | 0.07508000767946306 | 0.08853855012377168 | 0.09994937727503311 | 0.11182458833601834 |
| 27 | 0.06985908821576527 | 0.08017185227745025 | 0.0943598228711556 | 0.10855805993002561 | 0.11926306095722854 |
| 28 | 0.07476922509955214 | 0.08558359989814068 | 0.10022639992693635 | 0.11541477895810452 | 0.1271732638528928 |
| 29 | 0.08082697654221173 | 0.09275025575500671 | 0.10674528554019073 | 0.1217751009883986 | 0.1344831422782898 |
| 30 | 0.08646878995507364 | 0.09813325123006669 | 0.11267222418259133 | 0.12725420939287801 | 0.13926953632738423 |
| 31 | 0.09151610720807343 | 0.10385128682754727 | 0.11794062384310447 | 0.13236742750330485 | 0.14463687104722203 |
| 32 | 0.09644471072863017 | 0.10818117279519804 | 0.12286691608479247 | 0.1371665138984982 | 0.1507955221582018 |
| 33 | 0.09949317715060758 | 0.11140308251196819 | 0.12768748654593065 | 0.14278530800957942 | 0.15741777628373163 |
| 34 | 0.10113899378615351 | 0.11440405570419197 | 0.1318447325503226 | 0.14907986575631751 | 0.16784211995757845 |

S